secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2026-10-23T20:06:26+00:00
Accession:  0001517022-26-000075
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Akebia gets Nasdaq deficiency letter as stock closes below $1.00 for 30 straight days
--------------------------------------------------------------------------------

- Nasdaq Listing Qualifications notified Akebia on October 21, 2026 that its bid price closed under $1.00 for 30 consecutive business days, breaching Rule 5550(a)(2).
- Akebia has until April 19, 2027 (180 calendar days) to regain compliance by holding a closing bid of at least $1.00 for 10 straight business days.
- If it fails, Akebia could get a second 180-day period by meeting market-value and other initial listing standards and signaling a reverse split if needed.
- The notice has no immediate effect on listing; Akebia said it will monitor its bid price and may pursue a reverse stock split, with no assurance of regaining compliance.
- CEO John P. Butler signed the filing dated October 23, 2026; continued failure could lead to a Staff delisting determination and appeal to a Nasdaq Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/0001517022-26-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/akba-20261021.htm
  HTML page:      https://secwatch.observer/filing/0001517022-26-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer